Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis
13/03/2026 13:13
March 13 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS: IDMC RECOMMENDS DISCONTINUATION OF TACTI-004 PHASE III TRIAL AFTER INTERIM FUTILITY ANALYSIS IMMUTEP TO HALT ENROLMENT AND WIND DOWN TACTI-004 PHASE III STUDY Source text: ID:nBSE8hmsTG Further company coverage: REDY.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Immutep
See all newsBrief: Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance
Australia's Immutep extends gain on FDA orphan drug status for cancer drug
Brief: Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma
Brief: Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer
Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis